A market-proven health and wellness ROI software platform is available for acquisition or merger via an asset deal. This globally deployed Outcomes Management and ROI analytics and strategic planning solution is used by employers (both multinational and local), pharmaceutical companies, benefit consultants, healthcare payors, and wellness providers to measure outcomes and the return on investment (ROI) of intervention programs across physical, behavioral, and occupational health domains.
With proprietary software IP, global distribution relationships, and a curated database of country-specific productivity loss models, this asset is ideally positioned for integration into existing digital health, EAP, benefits consulting,HEOR/ Pharma or analytics businesses.
Asset Sale Includes
ROI© software platform (source code, models, calculators)
Global rights and trademarks
Proprietary data sets (productivity, cost, disease prevalence by country)
Client-facing training materials and user documentation
Distribution Network
Brand equity and promotional assets (multi-language website, articles, journal features)
Platform Strengths
Proven across 30+ countries including the U.S., Australia, South Africa,Canada, all European Countries, India, Mexico and Brazil.
Covers 25+ physical, behavioral, and infectious disease modules
Highly scalable model with low marginal costs and high-margin software licensing
Differentiated methodology developed with a leading global forecasting firm
Enables calculation of ROI, NPV, IRR, and breakeven points for employer-sponsored programs
Services
Licensing
Consulting
Training Courses
Support & Client Training
Promotion
Press/ LinkedIn Releases
Presentations and ROI training programs at conferences.
Articles in Journals
Web Site in different languages and Effective Call to Actions
Testimonials
Webinars
Word of Mouth
Future Development Plans:
Addition of New Countries
Addition of New Diseases and Conditions
Focus on Measuring Outcomes that are then converted to ROI
Currency: EUR
Target Price / Revenue: TBD
Target Price / EBITDA: TBD
